Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-12-19
2006-12-19
Ulm, John (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800
Reexamination Certificate
active
07151087
ABSTRACT:
The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
REFERENCES:
patent: 5440021 (1995-08-01), Chuntharapai et al.
patent: 5939320 (1999-08-01), Littman et al.
patent: 6025154 (2000-02-01), Li et al.
patent: 6265184 (2001-07-01), Gray et al.
patent: 6268477 (2001-07-01), Gray et al.
patent: 6344545 (2002-02-01), Allaway et al.
patent: 6448375 (2002-09-01), Samson et al.
patent: 6511826 (2003-01-01), Li et al.
patent: 6528625 (2003-03-01), Wu et al.
patent: 2001/0000241 (2001-04-01), Li et al.
patent: 2002/0076745 (2002-06-01), Li et al.
patent: 2002/0099176 (2002-07-01), Li et al.
patent: 2002/0106742 (2002-08-01), Samson et al.
patent: 2002/0110805 (2002-08-01), Samson et al.
patent: 2002/0110870 (2002-08-01), Samson et al.
patent: 2002/0132269 (2002-09-01), Li et al.
patent: 2002/0150888 (2002-10-01), Gray et al.
patent: 2003/0023044 (2003-01-01), Li et al.
patent: 2146328 (1994-05-01), None
patent: 0 310 136 (1989-04-01), None
patent: WO 94/12635 (1994-06-01), None
patent: WO 95/19436 (1995-07-01), None
patent: WO 96/39437 (1996-12-01), None
patent: WO 97/22698 (1997-06-01), None
patent: WO 97/32019 (1997-09-01), None
patent: WO 97/37005 (1997-10-01), None
patent: WO 97/44055 (1997-11-01), None
patent: WO 97/47318 (1997-12-01), None
Alkhatib et al., “CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-I,”Science, 272:1955-1958, Jun. 28, 1996.
Arenzana-Selsdedos et al., “HIV blocked by chemokine antagonist,”Nature383:400, Oct. 3, 1996.
Aversa et al., “An Interleukin 4 (IL-4) Mutant Protein Inhibits both IL-4 or IL-13-induced Human Immunoglobulin G4 (IgG4) and IgE Synthesis and B Cell Proliferation: Support for a Common Component Shared by IL-4 and IL-13 Receptors,”J. Exp. Med., 178: 2213-2218, Dec. 1993.
Carroll et al., “Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4+ T Cells,”Science276:273-276, Apr. 11, 1997.
Cocchi et al., “Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+T Cells,”Science, 270: 1811-1815, Dec. 15, 1995.
Combadiere and Murphy, “Cloning and Functional Expression of a Human Monocyte CC Chemokine Receptor,”The American Society for Cell Biology, Abstract; Submitted to 1995 Annual Meeting no later than Aug. 1, 1995.
Combadiere et al., “Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1α, MIP-1β, and RANTES,”J. Leuk. Biol. 60:147-152, Jul. 1996.
Combadiere and Murphy, “Cloning and Functional Expression of Two Human Monocyte CC Chemokine Receptors,”The American Society for Biochemistry and Molecular Biology, Abstract, submitted to 1996 Annual Meeting no later than Jan. 30, 1996.
Combadiere et al. “Cloning, Chromosomal Localization, and RNA Expression of a Human β Chemokine Receptor-Like Gene,”DNA and Cell Biol., 14(8):673-680, Nov. 8, 1995.
He et al., “CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia,”Nature385:645-649, Feb. 13, 1997.
Kaplan et al., “Chemokines and the allergic response,”Exp. Dermatol., 4(4 Pt 2):260-265, Aug. 1995 (ABSTRACT ONLY).
Margolis et al., “Host vs. Viral Factors in Human Tissues Infected In Vitro with HIV-1,”Mol. Path. ModelApr. 11, 1997.
McKenzie et al., “Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function,”Proc. Natl. Acad. Sci. USA, 90:3735-3739, Apr. 1993.
Minty et al., “Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses,”Nature, 362:248-250, Mar. 18, 1993.
Raport et al. “Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine Receptor (CCR5) for RANTES, MIP-1β, and MIP-1α,”J. Biol. Chem., 271(29);17161-17166, Jul. 19, 1996.
Robinson et al., “Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells,”Clin. Exp. Immunol., 101(3):398-407, Sep. 1995 (Abstract Only).
Samson et al., “Molecular Cloning and Fuctional Expression of a New Human CC-Chemokine Receptor Gene,”Biochem., 35(11):3362-3367, Mar. 1996.
Simmons et al., “Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist,”Science276:276-279, Apr. 11, 1997.
Uguccioni et al., “Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes,”Eur. J. Immunol., 25(1):64-68, Jan. 1995 (ABSTRACT ONLY).
Zimmerman et al., “Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical Phenotypes, Defined Racial Background, and Quantified Risk,”Mol. Med. 3(1):23-36, Jan. 1997.
Zurawski et al., “Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction,”EMBO J., 12(7):2663-2670, 1993.
Choe et al., “The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates,”Cell85:1135-1148 (Jun. 28, 1996).
Doranz et al., “A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors,”Cell85:1149-1158 (Jun. 28, 1996).
Dragic et al., “HIV-1 entry into CD4+cells is mediated by the chemokine receptor CC-CKR-5,”Nature381:667-673 (Jun. 20, 1996).
Kern and Dietrich, “Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution,”Blut52(4):249-254 (Apr. 1986)Abstract Only.
Kuhmann et al., “Frequent Substitution Polymorphisms in African Green Monkey CCR5 Cluster at Critical Sites for Infections by Simian Immunodeficienty Virus SIVagm, Implying Ancient Virus-Host Coevolution,”J Virology75(18):8449-8460 (Sep. 2001).
Mackewicz et al., “Role of β-Chemokines in Suppressing HIV Replication,”Science274:1393-1395 (Nov. 22, 1996).
Magnani et al., “The bone marrow in murine AIDS,”Br J Haematol. 84(3):539-841 (Jul. 1993)Abstract Only.
Combadiere et al., “Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor,”J. Biol. Chem. 270:16491-16494 (1995).
Feng et al., “HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein—Coupled Receptor,”Science272:872-877 (1996).
Gong et al., “RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors,”J. Biol. Chem. 271:10521-10527 (1996).
Rucker et al., “Regions in β-Chemokine Receptors CCR5 and CCR2b that Determine HIV-1 Cofactor Specificity,”Cell87:437-446 (1996).
Database PIR2 Accession No. G02653, Dec. 21, 1990 (also referred to as EMBL Accession No. A43113, Jul. 12, 1996).
Deng et al., “Identification of a major co-receptor for primary isolates of HIV-1,”Nature381:661-666 (Jun. 20, 1998).
Combadiere et al., “Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor,”J. Biol. Chem. 270:16491-16494
Alkhatib Ghalib
Berger Edward A.
Broder Christopher C.
Combadiere Christophe
Feng Yu
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
Ulm John
LandOfFree
CC chemokine receptor 5 DNA, new animal models and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CC chemokine receptor 5 DNA, new animal models and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CC chemokine receptor 5 DNA, new animal models and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3680029